Abstract
BackgroundThe aim of this study was to determine whether differing neoadjuvant chemotherapy (NAC) regimens for HER2 positive breast cancer (HER2+ BC) are associated with differing surgical complications. Our goal was to evaluate postoperative complications in HER2+ BC patients receiving NAC with Herceptin (trastuzumab, H) alone versus in combination with pertuzumab (HP). MethodsRetrospective chart review was performed of patients with Stage I-III HER2+ BC receiving NAC from 2007 to 2016. Demographics, tumor characteristics, surgical procedure, and 60-day postoperative complications were analyzed. ResultsH (n = 101) and HP (n = 132) were similar with respect to tumor characteristics and surgical procedure. Overall operative complications were similar between groups (p = 0.63), as were major versus minor complications (p = 1.0). Subgroup analysis identified a higher rate of complications for lumpectomy patients receiving HP versus H (p = 0.003). ConclusionsNeoadjuvant chemotherapy with HP is associated with increased complications after lumpectomy. Additional studies are warranted to assess causative factors for this observation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
